Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Tirzepatide was developed as a unimolecular dual agonist and moved through the SURPASS (type 2 diabetes) and SURMOUNT (obesity) Phase 3 programs to approval, becoming the first approved GLP-1/GIP dual agonist
Content current as of April 22, 2026
BPC-157 and TB-500 are not TGA-approved therapeutic agents for general use in Australia.
There is no single correct amount more water simply spreads the same 100 mg of peptide across a larger volume, which makes small doses easier to measure accurately
Gopal Grandhige and our clinical team oversee every step of the process, from prescribing the appropriate dosage to monitoring your response throughout your treatment
Developed in the 1980s by Professor Vladimir Khavinson, epithalon induces telomere elongation, thereby delaying aging of the reproductive and immune systems and increasing the lifespan of organisms
US$ 25.24
US$ 25.00
US$ 21.97
US$ 23.34
